Sugi Predict

Sugi Predict / Compounds / SCHEMBL3545687

SCHEMBL3545687

SCHEMBL3545687

COC(=O)CC1NCCNC1=O

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.57
▸ LMNA P02545 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ USP2 O75604 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ HTT P42858 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ KMT2A Q03164 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7093218 1.00 GLA (0.57) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL643035 0.83 GLA (0.62) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL7498041 0.83 GLA (0.62) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL4518744 0.82 GLA (0.53) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL4518742 0.82 GLA (0.53) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL5921835 0.78 GLA (0.55) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL5109358 0.78 GLA (0.55) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL3547552 0.77 LMNA (0.50) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL5103440 0.76 TSHR (0.53) GLALMNASMN1; SMN2TSHRL3MBTL1
SCHEMBL9021160 0.75 GAA (0.43) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 — — US disclosed
US-20090054460-A1 Piperazine derivatives and methods of use CHEN JIAN J 2009-02-26 — — US disclosed
US-20090054460-A1 Piperazine derivatives and methods of use CHEN JIAN J 2009-02-26 — — US disclosed
US-7393852-B2 Piperazine derivatives and methods of use AMGEN INC. (US) 2008-07-01 — — US disclosed
EP-1656355-B1 PIPERAZINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2008-03-12 — — EP disclosed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 — — EP disclosed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 — — US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS GLA 2985/4885LMNA 1192/4885SMN1; SMN2 2284/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS GLA 1400/4885LMNA 540/4885SMN1; SMN2 2243/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS GLA 1400/4885LMNA 540/4885SMN1; SMN2 2243/4885
US-20090054460-A1 Piperazine derivatives and methods of use PTGES, PTGES2, PTGIS GLA 1510/4885LMNA 2962/4885SMN1; SMN2 1545/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS GLA 942/4885LMNA 407/4885SMN1; SMN2 1888/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS GLA 942/4885LMNA 407/4885SMN1; SMN2 1888/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS GLA 942/4885LMNA 407/4885SMN1; SMN2 1888/4885
US-20060167247-A1 Urea inhibitors of MAP kinases MAPK1, MAP3K1, MAP3K20 GLA 2133/4885LMNA 2936/4885SMN1; SMN2 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.